A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2025-06-27
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and efficacy of once daily oral treatment with
orforglipron compared with placebo on body weight in adult participants with obesity or
overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22
visits.